PMID- 21772323 OWN - NLM STAT- MEDLINE DCOM- 20110926 LR - 20211203 IS - 1471-0048 (Electronic) IS - 1471-003X (Linking) VI - 12 IP - 8 DP - 2011 Jul 20 TI - Fighting neurodegeneration with rapamycin: mechanistic insights. PG - 437-52 LID - 10.1038/nrn3068 [doi] AB - A growing number of studies point to rapamycin as a pharmacological compound that is able to provide neuroprotection in several experimental models of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease and spinocerebellar ataxia type 3. In addition, rapamycin exerts strong anti-ageing effects in several species, including mammals. By inhibiting the activity of mammalian target of rapamycin (mTOR), rapamycin influences a variety of essential cellular processes, such as cell growth and proliferation, protein synthesis and autophagy. Here, we review the molecular mechanisms underlying the neuroprotective effects of rapamycin and discuss the therapeutic potential of this compound for neurodegenerative diseases. FAU - Bove, Jordi AU - Bove J AD - Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute-CIBERNED, 08035 Barcelona, Spain. FAU - Martinez-Vicente, Marta AU - Martinez-Vicente M FAU - Vila, Miquel AU - Vila M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20110720 PL - England TA - Nat Rev Neurosci JT - Nature reviews. Neuroscience JID - 100962781 RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Humans MH - Nerve Degeneration/*drug therapy/metabolism MH - Neurodegenerative Diseases/*drug therapy/metabolism MH - Signal Transduction/drug effects/physiology MH - Sirolimus/pharmacokinetics/*therapeutic use MH - TOR Serine-Threonine Kinases/*metabolism EDAT- 2011/07/21 06:00 MHDA- 2011/09/29 06:00 CRDT- 2011/07/21 06:00 PHST- 2011/07/21 06:00 [entrez] PHST- 2011/07/21 06:00 [pubmed] PHST- 2011/09/29 06:00 [medline] AID - nrn3068 [pii] AID - 10.1038/nrn3068 [doi] PST - epublish SO - Nat Rev Neurosci. 2011 Jul 20;12(8):437-52. doi: 10.1038/nrn3068.